Net Loss Per Share of Common Stock (Tables)

12 Months Ended

Dec. 31, 2018

Net Loss Per Share of Common Stock

Schedule of computation of basic and diluted earnings per share

	Year ended December 31,
	2018		2017
Basic and diluted net loss per share of common stock:
Net loss attributable to Onconova Therapeutics, Inc	$	(20,573,000)	$	(24,092,000)
Weighted average shares of common stock outstanding		4,124,073		600,022
Net loss per share of common stock—basic and diluted	$	(4.99)	$	(40.15)

Schedule of antidilutive securities which have been excluded from the computation of diluted weighted average shares outstanding

	December 31,
	2018	2017
Warrants	5,725,506	3,294,771
Stock options	379,328	894,996
	6,104,834	4,189,767